StockData
Kalaris Therapeutics, Inc. logo

Kalaris Therapeutics, Inc. (KLRS) stock

KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.37−0.06 (-4.20%)

Close on Nov 18, 2026Market cap $32.61MP/E –Yield –

Kalaris Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Kalaris Therapeutics's revenue for the twelve months ending Dec 31, 2019 was $165.00K. For fiscal 2019 it was $165.00K.

Annual revenue

PeriodPeriod endValueChange
FY2019Dec 31, 2019$165.00K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2019Dec 31, 2019$0–
Q3 FY2019Sep 30, 2019$0–

More Kalaris Therapeutics figures

See a number that looks wrong?